Adlai Nortye teams with Lilly and Merck KGaA on AN4035 trial
On 15 October 2026, Adlai Nortye entered clinical-trial collaboration and supply agreements with Eli Lilly and Merck KGaA for its investigational cancer therapy AN4035. The ongoing global Phase I study will test AN4035 alone and alongside cetuximab in patients with CEACAM5-enriched, RAS-driven solid tumors. Lilly will provide cetuximab for U.S. sites at no cost, while Merck KGaA will supply it without charge for sites in Australia and China.
Why it matters
The agreements expand AN4035's combination-testing program without requiring Adlai Nortye to purchase cetuximab for the specified trial locations. Adlai Nortye remains responsible for sponsoring the study, so the arrangement does not represent a licensing deal or funded co-development partnership.
Key facts
- 1Adlai Nortye will remain the sponsor of the AN4035 study. rttnews.com
- 2The trial will examine AN4035 both as a standalone treatment and in combination with cetuximab. tipranks.com
- 3Lilly is to provide cetuximab without charge at U.S. trial locations, while Merck KGaA is to furnish it at Australian and Chinese locations. tipranks.com
- 4AN4035 is an antibody-drug conjugate designed to target CEACAM5 and deliver a pan-RAS(ON) inhibitor payload. rttnews.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.